An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis

Completed · Phase 3

Conditions studied: Allergic Conjunctivitis

In brief

The purpose of this study is to evaluate the onset and duration of action of two concentrations of AKF-1 Ophthalmic Solution compared to vehicle in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis.

Key facts

Study ID

NCT01561521

Run by

Akorn, Inc.

People needed

90

Starts

2012-03-01

Expected to finish

2012-04-01

Last updated by the study team

2013-07-18

Who can join

Age: 10 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• positive bilateral conjunctival allergen challenge (CAC) reaction

You may not qualify if…

• known contraindications or sensitivities to the study medication or its components
• any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters
• use of disallowed medication during the period indicated prior to the enrollment or during the study

Where it is running

• Andover Eye Associates — Andover, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.